



Ag & Vet Weekly

All the news on ASX-listed agriculture and veterinary companies

SPECIAL SUMMER CATCH-UP EDITION

Monday, January 23, 2023

The Summer Catch-Up Edition was compiled by James Costa

- * CANN SELLS SOUTHERN FACILITY, ASSETS FOR \$5.5m TO SATIVITE
- * NORGES BANK TAKES 5% OF BEGA
- * MARCELO MORA EPSILON CO SEC; SONNY DIDUGU, LI LIN, MARK AUDET
- * MGC DRAWS FURTHER MERCER STREET \$800k
- * NORGES BANK BELOW 5% IN BEGA
- * PHOENIX TAKES 5.6% OF NUFARM
- * CRESO EGM 24.25% OPPOSE JAMES ELLINGFORD SHARES
- * AUSCANN LOSES DIRECTOR KRISTA BATES
- * MGC: DIRECTORS FEES REDUCED BY 55%, EVAN HAYES GOES
- * SUSTAINABLE NUTRITION REVENUE UP 80% TO \$3.4m, LOSS \$5.2m
- * JYSF TAKES 11.1% OF WELLNEX
- * PHARMAUST COMPLETES 1st MONEPANTEL MND/ALS COHORT
- * WELLNEX H1: REVENUE UP 53.4% TO \$13.2m
- * CRESO DRAWS DOWN OBSIDIAN \$500k
- * ZELIRA: CRESO REPAYS \$1.75m HEALTH HOUSE LOAN
- * CANN GROUP APPOINTS PETER KOETSIER CEO ON \$350k PA
- * WASHINGTON H SOUL PATTINSON REDUCES TO 19.4% IN CLOVER
- * NORGES BANK TAKES 5.2% OF BEGA
- * CRESO, MERNOVA TO SELL 7 MARIJUANA PRODUCTS IN CANADA

- * SEAFARMS CHAIR IAN TRAHAR BACKS SEA DRAGON, TAKES 29.2%
- * VASILIOS VOTSARIS TAKES 10.5% OF FOOD REVOLUTION
- * AVECHO TAKES TPM-VITAMIN K TO US FDA PRE-IND MEETING
- * ANATARA HAS 1.87 QUARTERS OF CASH
- * AWARE SUPER BELOW 5% OF NUFARM
- * FEDERAL GOVERNMENT APPOINTS CATHY MCGOWN AGRIFUTURES CHAIR
- * AGRIFUTURES \$49k RURAL WOMEN'S ACCELERATION GRANT
- * IFM, BONAFIDE TAKES 18.5% OF CLEAN SEAS
- * CANN GROUP 'SATIPHARM CBD NOT SUPERIOR TO PLACEBO FOR SLEEP'
- * PHARMAUST TAKES MONEPANTEL FOR MND TO HIGHER DOSE

The following articles appear in date order

Friday December 23, 2022

CANN SELLS SOUTHERN FACILITY, ASSETS FOR \$5.5m TO SATIVITE

[CANN GROUP](#)

Cann Group says Brisbane's Sativite Pty Ltd will buy its Melbourne 'Southern' growing and manufacturing facility and associated assets for a total \$5,480,000.

Cann Group said the sale included the land and building, business assets and employment of operating personnel, and access rights to certain "genetic strains".

NORGES BANK TAKES 5% OF BEGA

[BEGA CHEESE](#)

The Oslo, Norway-based Norges Bank says it has become substantial in Bega with 15,196,344 shares or 5.0005 percent of the company.

MARCELO MORA EPSILON CO SEC; SONNY DIDUGU, LI LIN, MARK AUDET

[EPSILON HEALTHCARE](#)

Epsilon says that Marcelo Mora will replace Sonny Didugu as company secretary, with Li Lin promoted to group financial controller, effective immediately.

Epsilon said that Mark Audet had resigned as joint company secretary for health reasons.

MGC DRAWS FURTHER MERCER STREET \$800k

[MGC PHARMACEUTICALS](#)

MGC says it has drawn \$A800,000 from its \$US10 million draw-down equity facility from Mercer Street, taking the total to \$US1.833 million.

In September, MGC said it had drawn down a total of \$US1.3 million from the New York-based Mercer Street facility (AVW: Sep 23, 2022).

Monday December 26, Tuesday December 27, 2022

ASX closed for Christmas, Boxing Day.

Wednesday December 28, 2022

NORGES BANK BELOW 5% IN BEGA

BEGA CHEESE

The Oslo, Norway-based Norges Bank says it has ceased its substantial holding in Bega after 2,463 “collateral shares” were returned from December 22 to 26, 2022

PHOENIX TAKES 5.6% OF NUFARM

NUFARM

The Giv'atayim, Israel-based Phoenix Group says it has become substantial in Nufarm with 21,290,883 shares or 5.597 percent of the company.

Thursday December 29, 2022

No announcements.

Friday December 30, 2022

CRESO EGM 24.25% OPPOSE JAMES ELLINGFORD SHARES

CRESO PHARMA

Creso says its extraordinary general meeting faced 73,206,129 votes (24.25%) in opposition to the issue of 4,000,000 shares to former director James Ellingford. Creso said all other resolutions passed easily (BD: Nov 28, 2022) (AVW: Dec 2, 2022). According to its most recent filing, Creso had a total of 1,835,962,135 shares on issue, meaning the votes against Mr Ellingford's shares amounted to 4.0 percent of the company, not sufficient to requisition extraordinary meetings.

Monday January 2, 2023

ASX closed for New Year's Day.

Tuesday January 3, 2023

AUSCANN LOSES DIRECTOR KRISTA BATES

AUSCANN GROUP

Auscann says Ms Krista Bates has resigned as non-executive director.

MGC: DIRECTORS FEES REDUCED BY 55%, EVAN HAYES GOES

MGC PHARMACEUTICALS

MGC says it will reduce directors' fees by up-to 55 percent, with shares to be issued in lieu of cash, and Evan Hayes has resigned as director, effective January 1, 2023.

Wednesday January 4, 2023

No announcements

Thursday January 5, 2023

SUSTAINABLE NUTRITION REVENUE UP 80% TO \$3.4m, LOSS \$5.2m

THE SUSTAINABLE NUTRITION GROUP

Sustainable Nutrition says revenue for the year to June 30, 2022 was up 80.2 percent to \$3,404,386, with net loss after tax up 19.3 percent to \$5,243,015.

Sustainable Nutrition said that diluted loss per share was down 9.9 percent to 4.8 cents and it had cash equivalents of \$378,420 at June 30, 2022, compared to \$10,573,053 at June 30, 2021.

JYSF TAKES 11.1% OF WELLNEX

WELLNEX LIFE

The Sydney-based Jeffrey Yeh and JYSF Management Pty Ltd say they have become substantial in Wellnex with 46,047,923 shares or 11.13 percent.

Friday January 6, 2023

PHARMAUST COMPLETES 1st MONEPANTEL MND/ALS COHORT

PHARMAUST

Pharmaust says it has completed the first cohort of six patients in its phase I/II monepantel trial for motor neurone disease and amyotrophic lateral sclerosis.

Monday January 9, 2023

WELLNEX H1: REVENUE UP 53.4% TO \$13.2m

WELLNEX LIFE

Wellnex says unaudited revenue for the six months to December 31, 2022 was up 53.4 percent to \$13.2 million, from the growth of its wholly-owned brands.

CRESO DRAWS DOWN OBSIDIAN \$500k

CRESO PHARMA

Creso says it has drawn an additional \$500,000 from its Obsidian Global GP LLC convertible note facility, taking the total to \$5.5 million (BD: Nov 1, 2022).

Tuesday January 10, 2023

ZELIRA: CRESO REPAYS \$1.75m HEALTH HOUSE LOAN

CRESO PHARMA, ZELIRA THERAPEUTICS, HEALTH HOUSE INTERNATIONAL

Zelira says Creso has repaid a \$1,750,000 loan which Creso absorbed after acquiring Health House for about \$4,600,000 (AVW: Nov 25, 2022).

CANN GROUP APPOINTS PETER KOETSIER CEO ON \$350k PA

CANN GROUP

Cann Group says it has appointed former Ipsen and Astrazeneca executive Peter Koetsier as its chief executive officer, replacing Peter Crock, from January 16, 2023.

Cann said that Mr Koetsier would have a base salary of \$350,000 a year, with short-term incentives of up-to 40 percent of his base salary and up to 4.5 million options exercisable at prices from 45 cents each to 75 cents each.

WASHINGTON H SOUL PATTINSON REDUCES TO 19.4% IN CLOVER

CLOVER CORPORATION

The Sydney-based Washington H Soul Pattinson say they have increased their holding in Clover from 33,926,867 shares (20.4%) to 32,340,217 shares (19.37%).

NORGES BANK TAKES 5.2% OF BEGA

BEGA CHEESE

The Oslo, Norway-based Norges Bank says it has become substantial in Bega with 15,673,810 shares or 5.16 percent of the company.

Wednesday January 11, 2023

CRESO, MERNOVA TO SELL 7 MARIJUANA PRODUCTS IN CANADA

CRESO PHARMA

Creso says its wholly-owned subsidiary Mernova Medicinal will sell seven new recreational marijuana products across Nova Scotia, Canada.

SEAFARMS CHAIR IAN TRAHAR BACKS SEA DRAGON, TAKES 29.2%

SEAFARMS GROUP

Seafarms chair Ian Trahar says “there is no technical reason why [Project Sea Dragon] should not proceed” and increased his holding in the company to 29.19 percent.

Mr Trahar said that through Gabor Holdings Pty Ltd he increased his holding in Seafarms from 1,316,616,676 shares (27.48%) to 1,411,603,263 shares (29.19%).

VASILIOS VOTSARIS TAKES 10.5% OF FOOD REVOLUTION

FOOD REVOLUTION GROUP

The Geelong-based Vasilios Votsaris says he has increased his holding in Food Revolution from 91,217,324 shares (9.63%) to 99,555,024 shares (10.52%).

Thursday January 12, 2023

AVECHO TAKES TPM-VITAMIN K TO US FDA PRE-IND MEETING

AVECHO BIOTECHNOLOGY

Avecho says it has presented its tocopheryl phosphate mixture injectable vitamin K to the US Food and Drug Administration in a pre-investigational new drug meeting.

Friday January 13, 2023

ANATARA HAS 1.87 QUARTERS OF CASH

ANATARA LIFE SCIENCES

Anatara says it has \$1,347,000 or 1.87 quarters of funding available, but expected to place the \$300,000 shortfall from its entitlement offer.

Anatara said it would continue to have the current level of net operating cash flows for “the time being”.

AWARE SUPER BELOW 5% OF NUFARM

NUFARM

The Sydney-based Aware Super Pty Ltd says it has ceased its substantial holding in Nufarm.

In 2021, Aware said it had 23,642,760 Nufarm shares (6.22%) (AVW: Nov 12, 2021).

Monday January 16, 2023

FEDERAL GOVERNMENT APPOINTS CATHY MCGOWN AGRIFUTURES CHAIR

FEDERAL GOVERNMENT, AGRIFUTURES AUSTRALIA

The Federal Government has appointed former independent member for Indi Cathy McGowan as the chair of Agrifutures Australia, effective from January 11, 2023.

Tuesday January 17, 2023

AGRIFUTURES \$49k RURAL WOMEN’S ACCELERATION GRANT

AGRIFUTURES AUSTRALIA

Agrifutures says it has \$7,000 Rural Women’s Acceleration Grants to seven women to foster growth and development for women in rural and emerging industries.

Agrifutures said the awards went to South Australia’s Alice Bennett, Western Australia’s Thea Walker, Victoria’s Nadine Holgate and Emma Goodall, Queensland’s Leanne Kruss and New South Wales’ Kate Webster and Sara McCarthy.

IFM, BONAFIDE TAKES 18.5% OF CLEAN SEAS

CLEAN SEAS SEAFOOD

IFM Independent Fund and Bonafide Global Fish Fund say they have increased their Clean Seas holding from 28,800,700 shares (17.42%) to 30,585,594 shares (18.49%).

Wednesday January 18, 2023

No announcements

Thursday January 19, 2023

CANN GROUP 'SATIPHARM CBD NOT SUPERIOR TO PLACEBO FOR SLEEP'

CANN GROUP

Cann Group says preliminary analysis of its Satipharm cannabidiol (CBD) capsules for sleep disturbances has “not shown a statistically superior response compared to placebo”. Last year, Cann Group said it had enrolled more than 212 patients in its randomized, double-blind, placebo-controlled phase III trial of marijuana-based low-dose Satipharm CBD capsules for short-term sleep disturbance.

The company said it expected the trial results to delay submission of its registration application to the Therapeutic Goods Administration for the indication.

Friday January 20, 2023

PHARMAUST TAKES MONEPANTEL FOR MND TO HIGHER DOSE

PHARMAUST

Pharmaust says it has approval to begin the next dosing level in its phase I/II trial of monepantel for motor neurone disease, after six patients reported no adverse events.